Novoxel® was founded in 2011 with the mission to transform fractional skin rejuvenation via focusing on improvement of the patient experience (excellent clinical results with very low downtime and little/no pain), reduced costs (to clinicians and patients), and environmental responsibility (no single-use consumables/packaging).  Our patented TMA® technology stands out as a patient-friendly, green, and versatile solution, backed by safety and reproducibility as documented in dozens of peer-reviewed clinical publications. Our close partnership with the medical community, including leading physicians on our advisory panel, drives us toward our vision.  Our Tixel® family of products are wonderfully unique because they can be used for multiple applications, on all skin types, all year round.

Known for innovative technology, Novoxel invests heavily in R&D and IP protection, holding over 65 patents and offering products in more than 50 countries. IP protection is vital to Novoxel's mission of enhancing aesthetic dermatologic treatments for patients and doctors.  In addition to our granted patents and design protections, we have additional IP protections issued or pending.  Novoxel’s trademarks include Tixel, Tixel C, Tixel 2, Thermo-Mechanical Action, TMA, and MezoTix.

In early 2024, the new Novoxel Inc. headquarters opened in Knoxville, Tennessee, with a management team boasting over 90 years of combined industry experience. Their shared goal is to redefine the fractional skin rejuvenation and medical laser device markets, expand Novoxel's footprint, and play a pivotal role in shaping the future landscape of the US market.

Tixel USA

Similar companies